

**FOR IMMEDIATE RELEASE – October 2, 2020**

**MindChild Medical, Inc. Announces Gates Funded UNC LABOR Study Sites All Using Meridian™ Fetal ECG Research Device**

The Meridian Fetal Research Device Accurately Extracts Fetal ECG to Enable Analytics on Fetal ECG Morphology, Heart Rate, Heart Rate Variability and Uterine Activity Using Surface Electrodes

(North Andover, Massachusetts), MindChild Medical, Inc. today announced it has shipped 24 Meridian M110R Fetal Research Devices and 8,000 electrode patch sets to the UNC LABOR Study's sites in developing countries of Zambia, Ghana, and India. All of the sites are fully trained on the use of Meridian and actively enrolling subjects. The hospital locations are:

- Women and Newborn Hospital at University Teaching Hospital, Lusaka, Zambia
- Korle Bu Teaching Hospital, Accra, Ghana
- Jawaharlal Nehru Medical College Women's and Children's Health Research Unit, Belgaum, Karnataka, India
- Fakir Mohan Medical College and Hospital, Balasore, Odisha, India

Study information can be found at [www.clinicaltrials.gov](http://www.clinicaltrials.gov) identifier NCT04102644.

**About the LABOR Study**

The Limiting Adverse Birth Outcomes in Resource-Limited Settings (LABOR) study, funded by a \$14 million grant from the Bill & Melinda Gates Foundation to the University of North Carolina, will focus on the period of pregnancy between the onset of labor through delivery. It will evaluate 15,000 women at high-volume clinical sites in three developing countries. The team will provide wearable physiologic sensors to monitor laboring mothers and their fetuses and carefully document their clinical course and birth outcomes.



Using participant data recorded and produced by the Meridian M110R Fetal Research Device, researchers will develop new algorithms that can both identify individual women's risk of specific adverse outcomes and help predict and plan for the specific interventions women will likely need. These precision approaches can lead to earlier intervention and better health outcomes for mothers and newborns.



### **About the Meridian Non-Invasive Fetal ECG Research Device**

The Meridian M110R Fetal Research Device is an external fetal monitor using abdominal surface electrodes that measures and records electrophysiological signals of the mother and fetus. In real-time, Meridian also extracts and records the fetal ECG waveform, fetal and maternal heart rate, fetal and maternal R-R interval, uterine muscle contraction signal, and processing statistics including fetal and maternal ECG signal quality.

MERIDIAN M110R Fetal Research Device is designed for women who are  $\geq 24$  completed weeks, with singleton pregnancies, using surface electrodes on the maternal abdomen. MERIDIAN is intended for use by healthcare professionals in a clinical setting.

### **About MindChild Medical, Inc.**

MindChild Medical, Inc., is a privately funded medical device company founded in 2008. MindChild's principal technology platform, the Meridian non-invasive fetal electrocardiograph (ECG) monitor, is designed to report fetal heart rate data equivalent to the gold standard fetal scalp electrode in addition to novel ECG metrics intended to provide obstetricians a deeper understanding of fetal/maternal health and management.

MindChild was co-founded by Adam Wolfberg, MD, Assistant Professor, Tufts Medical Center, Gari Clifford, PhD, previously Principal Research Scientist at Harvard-MIT Division of Health and Science Technology (currently Interim Chair, Associate Professor, Biomedical Informatics (Emory University)),

MindChild Medical, Inc.  
1600 Osgood Street  
Suite 2017  
N. Andover, MA 01845  
T: 978.975.1160  
[www.mindchild.com](http://www.mindchild.com)



James Robertson, President and CEO, and Jay Ward, Executive Vice President, both of E-TROLZ, Inc. MindChild has exclusively licensed intellectual property from the Massachusetts Institute of Technology, Tufts Medical Center and E-TROLZ, Inc., a Massachusetts technology company that develops and commercializes breakthrough physiologic monitoring platforms for a wide variety of applications. For more information, please visit [www.mindchild.com](http://www.mindchild.com).

#### Contacts

MindChild Medical, Inc.  
Jay Ward, 978-975-1160 x113  
EVP  
[jay.ward@mindchild.com](mailto:jay.ward@mindchild.com)